Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Looks like IM phase III test has been successful

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Mar 21, 2023 10:35am

147 Views

Post# 35351106

RE:RE:Looks like IM phase III test has been successful

Thatarticle was translated from Chinese by Google translate so the "successful" comment may not have translated perfectly accurately. It may have meant "if it is successful". I don't think this is anything that will move the stock anyway.

It will be a long time before the next version of Trogarzo gets approved, if ever, given they are just completing safety studies now. I am not sure what the comment about more interest in it means though. Perhaps they will sell it to another drug company as Taimed seems to be focusing more on drug manufacturing now then drug development.